I
218.57
-6.93 (-3.07%)
| 前收盘价格 | 225.50 |
| 收盘价格 | 225.69 |
| 成交量 | 423,401 |
| 平均成交量 (3个月) | 980,883 |
| 市值 | 15,386,421,248 |
| 市盈率 (P/E TTM) | 62.99 |
| 预期市盈率 (P/E Forward) | 36.76 |
| 价格/销量 (P/S) | 6.11 |
| 股市价格/股市净资产 (P/B) | 10.70 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业毛利率 | 18.29% |
| 营业利益率 (TTM) | 15.61% |
| 稀释每股收益 (EPS TTM) | 5.54 |
| 季度收入增长率 (YOY) | 28.80% |
| 季度盈利增长率 (YOY) | -31.30% |
| 总债务/股东权益 (D/E MRQ) | 131.40% |
| 流动比率 (MRQ) | 4.47 |
| 营业现金流 (OCF TTM) | 406.50 M |
| 杠杆自由现金流 (LFCF TTM) | 84.25 M |
| 资产报酬率 (ROA TTM) | 6.94% |
| 股东权益报酬率 (ROE TTM) | 37.92% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | Insulet Corporation | 看跌 | 看涨 |
AIStockmoo 评分
1.1
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.13 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Mid Growth |
| 内部持股比例 | 0.29% |
| 机构持股比例 | 102.56% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 435.00 (Canaccord Genuity, 99.02%) | 购买 |
| 中 | 340.00 (55.56%) | |
| 低 | 274.00 (Barclays, 25.36%) | 卖出 |
| 平均值 | 344.42 (57.58%) | |
| 总计 | 11 购买, 1 卖出 | |
| 平均价格@调整类型 | 251.62 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 338.00 (54.64%) | 购买 | 238.82 |
| 19 Feb 2026 | 345.00 (57.84%) | 购买 | 249.10 | |
| Bernstein | 19 Feb 2026 | 330.00 (50.98%) | 购买 | 249.10 |
| 09 Jan 2026 | 380.00 (73.86%) | 购买 | 289.04 | |
| Canaccord Genuity | 19 Feb 2026 | 435.00 (99.02%) | 购买 | 249.10 |
| Evercore ISI Group | 19 Feb 2026 | 340.00 (55.56%) | 购买 | 249.10 |
| Goldman Sachs | 19 Feb 2026 | 326.00 (49.15%) | 购买 | 249.10 |
| JP Morgan | 19 Feb 2026 | 340.00 (55.56%) | 购买 | 249.10 |
| Leerink Partners | 19 Feb 2026 | 360.00 (64.71%) | 购买 | 249.10 |
| Oppenheimer | 19 Feb 2026 | 300.00 (37.26%) | 购买 | 249.10 |
| Truist Securities | 19 Feb 2026 | 360.00 (64.71%) | 购买 | 249.10 |
| BTIG | 18 Feb 2026 | 380.00 (73.86%) | 购买 | 258.07 |
| Stifel | 04 Feb 2026 | 350.00 (60.13%) | 购买 | 251.24 |
| Barclays | 12 Jan 2026 | 274.00 (25.36%) | 卖出 | 278.55 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合